Chirgwin, J; Sun, Z; Smith, I; Price, K N; Thürlimann, B; Ejlertsen, B; Bonnefoi, H; Regan, M M; Goldhirsch, A; Coates, A S (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131(1):295-306.
Regan, M M; Neven, P; Giobbie-Hurder, A; Goldhirsch, A; Ejlertsen, B; Mauriac, L; Forbes, J F; Smith, I; Láng, I; Wardley, A; Rabaglio, M; Price, K N; Gelber, R D; Coates, A S; Thürlimann, B (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncology, 12(12):1101-1108.